

CITATION REPORT

List of articles citing

Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression

DOI: 10.1016/j.jaac.2013.11.005

Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 174-87.

Source: <https://exaly.com/paper-pdf/59611905/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
117	Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. 2014 , 15, 1601-10		12
116	A review of atomoxetine effects in young people with developmental disabilities. 2014 , 35, 1412-24		29
115	Delivering evidence-based treatments for child attention-deficit/hyperactivity disorder (ADHD) in the context of parental ADHD. 2014 , 16, 474		24
114	Traditional Chinese medicine in the treatment of ADHD: a review. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2014 , 23, 853-81	3.3	19
113	Meta-analysis and moderator analysis: can the field develop further?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014 , 53, 135-7	7.2	15
112	Influence of DAT1 and COMT variants on neural activation during response inhibition in adolescents with attention-deficit/hyperactivity disorder and healthy controls. 2015 , 45, 3159-70		8
111	The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2015 , 24, 43-54		76
110	Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. 2015 , 60, 62-76		50
109	Central Nervous System Stimulants and Drugs That Suppress Appetite. 2015 , 37, 1-13		
108	A critical appraisal of atomoxetine in the management of ADHD. 2016 , 12, 27-39		19
107	Interventions for Attention-Deficit Hyperactivity Disorder: A Year in Review. 2015 , 2, 38-45		5
106	The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. 2015 , 29, 131-51		28
105	Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety. 2015 , 136, 351-9		27
104	Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes. 2015 , 8, 383-97		15
103	Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015 , 54, 728-36	7.2	50
102	Antipsychotic Use in Youth Without Psychosis: A Double-edged Sword. 2015 , 72, 859-60		22
101	Treatment of Childhood Oppositional Defiant Disorder. 2015 , 1, 155-167		1

100	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials. 2015 , 4, 19		28
99	Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015 , 54, 905-15	7.2	77
98	Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment. 2016 , 112, 1085-101		7
97	. 2016 ,		4
96	Sleep Problems in Children with Attention Deficit/Hyperactivity Disorder: Current Status of Knowledge and Appropriate Management. 2016 , 18, 76		32
95	References. 2016 , 227-310		
94	Effects of Methylphenidate and Atomoxetine on Development of the Brain. 2016 , 825-845		1
93	Psychiatric Symptoms and Comorbidities in Autism Spectrum Disorder. 2016 ,		7
92	Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial. 2016 , 30, 459-67		13
91	Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016 , 55, 868-876.e2	7.2	21
90	Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children. 2016 , 30, 976-82		7
89	Pharmacotherapy of conduct disorder: Challenges, options and future directions. 2016 , 30, 967-75		8
88	Pharmacotherapy in Psychiatric Disorders of Children: Current Evidence and Trends. 2016 , 49, 219-225		6
87	Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis. 2016 , 46, 1791-807		42
86	Attention-Deficit Hyperactivity Disorder and Autism Spectrum Disorder. 2016 , 79-91		2
85	Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder. 2016 , 26, 798-806		9
84	The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. 2016 , 30, 603-28		33
83	Pharmacovigilance in Psychiatry. 2016 ,		4

82	Attention-Deficit Hyperactivity Disorder Across the Lifespan. 2016 , 14, 46-53	1
81	Impulsive Aggression as a Comorbidity of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. 2016 , 26, 19-25	60
80	Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe. 2016 , 36, 1-25	28
79	Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. 2016 , 233, 187-97	53
78	Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology. 2017 , 9, 149-160	7
77	Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients. 2017 , 20, 519-528	63
76	Pediatric Psychopharmacology: a Primer for the Treatment of Common Mental Health Conditions. 2017 , 3, 57-68	
75	Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism. 2017 , 27, 708-714	8
74	Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients. 2017 , 234, 2657-2671	12
73	Attention Deficit Hyperactivity Disorder and Associated Cognitive Dysfunction in Pediatric Epilepsy. 2017 , 24, 282-291	4
72	Attention-Deficit/Hyperactivity Disorder. 2017 , 114, 149-159	42
71	Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder. <i>Frontiers in Psychiatry</i> , 2017 , 8, 229	5 8
70	The effect of atomoxetine on random and directed exploration in humans. 2017 , 12, e0176034	37
69	New Research. 2017 , 22, 12-14	
68	Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial. 2018 , 102, 57-64	9
67	Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat. 2018 , 70, 34-45	5
66	Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine. 2018 , 34, 619-632	3
65	Le TDAH chez les enfants et les adolescents, partie 2 : le traitement. 2018 , 23, 473-484	78

64	ADHD in children and youth: Part 2-Treatment. 2018 , 23, 462-472		19
63	Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. 2018 , 28, 1059-1088		216
62	Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: A meta-analysis. 2018 , 238, 161-178		22
61	Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients. 2018 , 18, 168		17
60	Treatment Implications for ADHD Youth with Mood and Anxiety Comorbidity. 2018 , 5, 73-97		1
59	The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials. 2018 , 28, 494-507		9
58	The Role of the Gut-Brain Axis in Attention-Deficit/Hyperactivity Disorder. 2019 , 48, 407-431		20
57	Atomoxetine improves memory and other components of executive function in young-adult rats and aged rhesus monkeys. 2019 , 155, 65-75		14
56	Understanding Chronic Aggression and Its Treatment in Children and Adolescents. 2019 , 21, 123		4
55	Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review. 2019 , 34, 57-64		5
54	Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder. 2019 , 29, 9-19		5
53	Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis. 2019 , 12, 542-552		22
52	Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder - implications for clinical recognition and intervention. 2019 , 60, 133-150		115
51	Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. 2020 , 1-9		6
50	Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. 2020 , 19, 214-232		57
49	ADHS im Kindes- und Jugendalter. Update 2020. 2020 , 55, 1-22		
48	Relationship Between Treatment Duration and Efficacy of Pharmacological Treatment for ADHD: A Meta-Analysis and Meta-Regression of 87 Randomized Controlled Clinical Trials. <i>Journal of Attention Disorders</i> , 2021 , 25, 1352-1361	3.7	4
47	Attention-deficit hyperactivity disorder. 2020 , 395, 450-462		151

46	[Attention deficit hyperactivity disorder in childhood and adolescence : Current state of research]. 2020 , 91, 599-603		1
45	Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions. 2021 , 26, 202-221		8
44	Attention-Deficit/Hyperactivity Disorder (ADHD), antisociality and delinquent behavior over the lifespan. 2021 , 120, 236-248		13
43	Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET. 2021 , 26, 1009-1018		11
42	Psychopharmacology of Williams syndrome: safety, tolerability, and effectiveness. 2021 , 20, 293-306		1
41	Deficient Emotional Self-Regulation and Sleep Problems in ADHD with and without Pharmacological Treatment. <i>Journal of Attention Disorders</i> , 2021 , 1087054720986242	3-7	1
40	Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Systematic Scoping Review. 2021 , 4, e215335		17
39	Systematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: implications for use in adult patients. 2021 , 1-13		
38	Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. 2021 , 43, 684-700		14
37	Liver Enzyme Elevation from Atomoxetine Use-A Case Report. 2021 , 31, 322-323		
36	A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder. 2021 , 41, 370-380		13
35	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. 2021 , 20, 244-275		12
34	Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder. 2021 , 75, e14330		3
33	Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review. 2021 , 10, 499-522		4
32	Exploring the Effects of Pharmacological, Psychosocial, and Alternative/Complementary Interventions in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Meta-Regression Approach. 2021 , 24, 776-786		2
31	ADHD and Its Therapeutics. 2021 , 8, 175-183		0
30	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. 2021 , 128, 789-818		92
29	Safety and Tolerability of Medications for ADHD. 2016 , 233-253		2

28	Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD. 2017 , 16, 1335-1345		17
27	Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature. 2021 , 35, 203-210		1
26	Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release. 2018 , 15, 90-93		9
25	The Guideline of Diagnosis and Treatment of Attention-Deficit Hyperactivity Disorder: Developed by ADHD Translational Research Center. 2016 , 27, 236-266		5
24	Effects of somatic treatments on suicidal ideation and completed suicides. 2021 , 11, e2381		2
23	Efectividad cognitiva del metilfenidato y de la atomoxetina en el trastorno por déficit de atención con hiperactividad: una revisión. 2016 , 33, 367-377		
22	Verhaltenstherapie und psychopharmakologische Behandlung. 2019 , 929-941		
21	Nonadherence in Childhood Disorders: Attention-Deficit/Hyperactivity Disorder. 2019 , 17-30		0
20	Clinical and Neuropsychological Factors Associated with Treatment Response and Adverse Events of Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder. 2019 , 30, 74-82		1
19	Children and Adolescents. 2019 ,		
18	Children and Adolescents. 2019 ,		
17	Attention Deficit Hyperactivity Disorder. 2021 ,		
16	Effect of Atomoxetine on Behavioral Difficulties and Growth Development of Primary School Children with Attention-Deficit/Hyperactivity Disorder: A Prospective Study.. <i>Children</i> , 2022 , 9,	2.8	
15	The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 780921	5	0
14	The Role of Glutamate Dysregulation in the Etiology of ADHD. 2022 , 467-492		
13	Updates in Pharmacologic Strategies for Emotional Dysregulation in Attention Deficit Hyperactivity Disorder. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2022 ,	3.3	1
12	Personalization of pharmacological treatments for ADHD: Why it is advisable and possible options to achieve it.. <i>Current Topics in Medicinal Chemistry</i> , 2022 ,	3	0
11	Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2022 ,	3.3	

10	From Structural Disparities to Neuropharmacology. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2022 ,	3-3	
9	Animal Models of ADHD?. <i>Current Topics in Behavioral Neurosciences</i> , 2022 ,	3-4	
8	A mechanistic model of ADHD as resulting from dopamine phasic/tonic imbalance during reinforcement learning. <i>Frontiers in Computational Neuroscience</i> , 16,	3-5	○
7	Complementary and Alternative Medicine Use by ADHD Patients: A Systematic Review. <i>Journal of Attention Disorders</i> , 108705472211115	3-7	○
6	Psychosocial Interventions for Attention Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis by the CADDRA Guidelines Work GROUP. 2022 , 12, 1023		○
5	Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder. 2022 , 10,		○
4	Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.		○
3	Interventions for ADHD in childhood and adolescence: A systematic umbrella review and meta-meta-analysis. 2023 , 102, 102271		○
2	The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications. 2023 , 149, 105149		○
1	Oppositionelle, aggressive und dissoziale Verhaltensstörungen in Kindheit und Jugend. 2023 , 1-24		○